Takara Holdings announced that it would postpone the release of its financial results for April–June 2026 due to concerns regarding the accounting treatment at its U.S. subsidiary. The company received an initial notification from its auditor regarding concerns over Takara Bio USA's accounting treatment and said it could not reach a conclusion until it had confirmed the facts.
Takara Holdings announced on the 12th that it planned to postpone disclosure of its financial results for April–June 2026. The postponement follows concerns raised regarding the accounting treatment at Takara Bio USA, the group's U.S. subsidiary.
According to the company, its auditor notified it late at night that there were concerns, and contacted it on the morning of the 7th to say that it could not state a conclusion until confirmation of the facts and an assessment of the impact on business performance had been completed. The company is currently conducting an investigation involving lawyers and certified public accountants.
Takara Bio USA is based in San Jose, California, and is reported to have generated approximately $107.2 million in revenue for the fiscal year ended March 2026. The date for announcing the company's April–June results remains undecided.
Nikkei's report on the matter describes the reason for the postponement announced by Takara Holdings and the status of its investigation. At present, the article does not specify any direct impact on announcements or figures at other companies.